Sort   by:  
 Page size 
ProteomicsInsight into the Human Pathodegradome of the V8 protease from Staphylococcus aureus
The major human pathogen Staphylococcus aureus possesses ten extracellular proteases that are central to the virulence process. While some host targets of these and other bacterial proteases are known, a major bottleneck to the study of their function is the low-throughout nature of substrate identi...
ORGANISM(S): Homo sapiens (Human) Staphylococcus aureus 
2021-03-29 | PXD014797 | Pride
Host-pathogen interactions Immunology Microbiology N-terminomics Staphylococcus aureus Degradomics 
TranscriptomicsCharacterizing the transcriptional adaptation of Staphylococcus aureus to stationary phase growth
Staphylococcus aureus is an important human pathogen that causes life-threatening infections, and is resistant to the majority of our antibiotic arsenal. This resistance is complicated by the observation that most antibacterial agents target actively growing cells, thus, proving ineffective against ...
ORGANISM(S): Staphylococcus aureus 
2016-05-18 | E-GEOD-77242 | biostudies-arrayexpress
TranscriptomicsNsaRS is a Cell-Envelope-Stress Sensing Two-Component System of Staphylococcus aureus
S. aureus possesses 16 two-component systems (TCS), two of which (GraRS & NsaRS) belong to the intramembrane-sensing histidine kinase (IM-HK) family, conserved within the firmicutes. NsaRS has recently been documented as being important for nisin-resistance in S. aureus. In this study we present a d...
ORGANISM(S): Staphylococcus aureus 
2011-05-16 | E-GEOD-27061 | biostudies-arrayexpress
MetabolomicsFeatures of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study
Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year after discharge. Modeling identified 4 PRO clusters based on reported deficit...
2024-01-12 | MTBLS850 | MetaboLights
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
Sort   by:  
 Page size